SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO )
CNTO 0.000010000.0%Mar 7 3:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: PawPr who wrote (639)4/9/1998 1:13:00 AM
From: FNS  Read Replies (1) of 965
 
Mighty quiet thread! Wake up! Couple of things to think about:

- CNTO should be reporting earnings come 4/21. Any predictions?
(Hope they do as well s BGEN/in line!).

- FDA to review Avakine in May (???--comment from previous post).

- CNTO has corrected quite a bit...pretty close to the bottom channel of the weekly closings on the yearly chart. If it can close above 40 this week. the longer term uptrend remains intact. IMHO! However, MRK's drug (another Reopro competitor) could negatively impact CNTO as the FDA looks at it shortly (4/10 I believe was previously suggested?).

Regarding FDA approval of Avakine, any further comments on potential issues; i.e., dosage and timing requirements as previously cited?

Seems like momentum has dissipated due to delays of anticipated events and now these events are almost anticlimatic! (IMO!)

Hopefully Reopro will prevail and sales increase as forecasted (?) and Avakine will be approved...and CNTO will be able to market it QUICKLY in USA.

FNS



Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext